NEW YORK – InformedDNA on Wednesday said it has acquired Coriell Life Sciences, a pharmacogenomics and clinical-decision support company.

纽约——InformedDNA周三表示已收购药理基因组学和临床决策支持公司Coriell Life Sciences。

St. Petersburg, Florida-based InformedDNA, which provides genetic counseling and genetic testing interpretation services to payors, hospital systems, and other healthcare organizations, will integrate PGx capabilities from Coriell, a Philadelphia-based company that sells solutions to large employers, payors, hospital systems, and research institutions..

总部位于佛罗里达州圣彼得堡的InformedDNA为支付方、医院系统和其他医疗保健组织提供基因咨询和基因测试解读服务，将整合来自Coriell的PGx能力，这家总部位于费城的公司向大型雇主、支付方、医院系统和研究机构提供解决方案。

The companies have begun integrating Coriell's PGx services into InformedDNA's DNAimpact precision health platform.

这些公司已经开始将 Coriell 的 PGx 服务整合到 InformedDNA 的 DNAimpact 精准健康平台中。

InformedDNA sells DNAimpact to payors and employers as a program that screens and educates members or employees and their healthcare providers about health risks, paired with genetic testing and counseling to create personalized care plans. The combined offering will also identify best-fit medications based on PGx results..

InformedDNA 向支付方和雇主销售 DNAimpact，作为一个筛查和教育成员或员工及其医疗保健提供者关于健康风险的项目，结合基因检测和咨询来制定个性化护理计划。该组合产品还将根据药物基因组学 (PGx) 结果确定最适合的药物。

'Pharmacogenomics is a critical aspect of personalized precision healthcare, and it presents an important opportunity to expand our ability to drive better patient outcomes,' InformedDNA CEO Surya Singh said in a statement, noting that Coriell has a presence selling to public employer plans, which he said are currently underserved by precision medicine..

“药物基因组学是个性化精准医疗的重要组成部分，它为我们提供了一个拓展能力、推动患者获得更好疗效的重要机会。”InformedDNA首席执行官苏里亚·辛格在一份声明中表示，并指出科里尔公司在向公共雇主计划销售方面占有市场，他认为这些计划目前在精准医疗领域服务不足。

Coriell CEO Scott Megill, who cofounded the company, will join InformedDNA in the new role of chief commercial officer.

Coriell首席执行官兼联合创始人斯科特·梅吉尔将加入InformedDNA，担任首席商务官的新职务。

Financial details of the transaction were not disclosed.

交易的财务细节未被披露。